SCHEMBL22718340

SCHEMBL22718340

Cc1c(-c2cn(C)cn2)cccc1S(N)(=O)=O

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 2/20 0.40
▸ CYP2E1 P05181 1/20 0.40
▸ CYP2A6 P11509 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2B6 P20813 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ HCRTR1 O43613 1/20 0.38
▸ HCRTR2 O43614 1/20 0.38
▸ CA1 P00915 2/20 0.36
▸ CA2 P00918 2/20 0.36
▸ CA9 Q16790 2/20 0.36
▸ CA12 O43570 1/20 0.36
▸ PIK3CD O00329 1/20 0.36
▸ CASP6 P55212 1/20 0.36
▸ ALOX5AP P20292 1/20 0.36
▸ FEN1 P39748 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ GAA P10253 1/20 0.35
▸ STAT3 P40763 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29704120 1.00 LRRK2 (0.40) LRRK2CYP2E1CYP2A6CYP2C9CYP2B6
SCHEMBL22635577 0.87 CYP2C9 (0.43) LRRK2CYP2E1CYP2A6CYP2C9CYP2B6
SCHEMBL18378721 0.77 CYP2C19 (0.44) LRRK2CYP2E1CYP2A6CYP2C9CYP2B6
SCHEMBL31565756 0.76 LMNA (0.46) CYP2C9CYP2C19CA1CA2CA9
SCHEMBL17194995 0.75 LRRK2 (0.40) LRRK2CYP2E1CYP2A6CYP2C9CYP2B6
SCHEMBL9959654 0.72 STAT3 (0.42) LRRK2HCRTR1HCRTR2CA1CA2
SCHEMBL29704124 0.72 CA2 (0.51) LRRK2CYP2E1CYP2A6CYP2C9CYP2B6
SCHEMBL31331822 0.72 PIK3CD (0.43) LRRK2CYP2E1CYP2A6CYP2C9CYP2B6
SCHEMBL28732947 0.71 BRD4 (0.53) CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19
SCHEMBL29602351 0.71 BRD4 (0.53) CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3976194-A2 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2022-04-06 — — EP disclosed
WO-2020243415-A2 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2020-12-03 — — WO disclosed
Send feedback